These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2151728)

  • 21. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of various antiplatelet agents on acute arterial thrombosis in the rat.
    Bernat A; Mares AM; Defreyn G; Maffrand JP; Herbert JM
    Thromb Haemost; 1993 Nov; 70(5):812-6. PubMed ID: 8128439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
    Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
    Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation.
    Janssens WJ; Cools FJ; Hoskens LA; Van Nueten JM
    Thromb Haemost; 1990 Aug; 64(1):91-6. PubMed ID: 2148850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage.
    Imura Y; Terashita Z; Nishikawa K
    Thromb Res; 1990 Jul; 59(1):195-205. PubMed ID: 2119075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
    Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
    J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
    Vanden Bossche H; Willemsens G; Bellens D; Janssen PA
    Biochem Pharmacol; 1992 Feb; 43(4):739-44. PubMed ID: 1540227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046).
    Hiraku S; Taniguchi K; Wakitani K; Omawari N; Kira H; Miyamoto T; Okegawa T; Kawasaki A; Ujiie A
    Jpn J Pharmacol; 1986 Jul; 41(3):393-401. PubMed ID: 3093741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa.
    Sinha AK; Rao AK; Willis J; Colman RW
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6086-90. PubMed ID: 6577468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.